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 Background The National Cancer Institute’s Symptom Management and Health-Related Quality of Life Steering Committee 
held a clinical trials planning meeting (September 2011) to identify a core symptom set to be assessed across 
oncology trials for the purposes of better understanding treatment efficacy and toxicity and to facilitate cross-
study comparisons. We report the results of an evidence-synthesis and consensus-building effort that culminated 
in recommendations for core symptoms to be measured in adult cancer clinical trials that include a patient-
reported outcome (PRO).
 Methods We used a data-driven, consensus-building process. A panel of experts, including patient representatives, con-
ducted a systematic review of the literature (2001–2011) and analyzed six large datasets. Results were reviewed 
at a multistakeholder meeting, and a final set was derived emphasizing symptom prevalence across diverse 
cancer populations, impact on health outcomes and quality of life, and attribution to either disease or anticancer 
treatment.
 Results We recommend that a core set of 12 symptoms—specifically fatigue, insomnia, pain, anorexia (appetite loss), 
dyspnea, cognitive problems, anxiety (includes worry), nausea, depression (includes sadness), sensory neuropa-
thy, constipation, and diarrhea—be considered for inclusion in clinical trials where a PRO is measured. Inclusion 
of symptoms and other patient-reported endpoints should be well justified, hypothesis driven, and meaningful to 
patients.
 Conclusions This core set will promote consistent assessment of common and clinically relevant disease- and treatment-
related symptoms across cancer trials. As such, it provides a foundation to support data harmonization and con-
tinued efforts to enhance measurement of patient-centered outcomes in cancer clinical trials and observational 
studies.
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Beyond traditional measures of therapeutic response (ie, survival 
and tumor response), the efficacy and toxicity of an intervention 
can be more fully interpreted through evaluation of disease- and 
treatment-related symptoms. Toxicities often develop several 
weeks after starting cancer treatment, and many are subjective (eg, 
fatigue, headache, neuropathy) and thus best captured by patient 
self-report (1).
Symptom screening offers an opportunity to improve care qual-
ity for patients participating in clinical trials (2), thereby improv-
ing treatment adherence and clinical outcomes, particularly in our 
contemporary treatment environment where use of oral agents is 
increasing (3,4). Identification of a core set of symptoms and/or 
health-related quality-of-life (HRQOL) domains to be measured 
across trials could enhance clinical and population research and 
improve supportive care (5).
The lack of an agreed-upon core set of symptoms to be collected 
in adult oncology treatment trials reflects the heterogeneity of can-
cer types and effects of treatments on patients’ lives. For example, 
treatments for localized prostate cancers are associated with diar-
rhea, urinary incontinence, and impotence (6–9), whereas treatments 
for head and neck cancers are associated with mucositis, xerostomia, 
dysphagia, weight loss, and speech alterations (10,11). However, sev-
eral symptoms, including fatigue, pain, insomnia, gastrointestinal 
symptoms, anxiety, and depressed mood, are commonly experienced 
across different cancer sites and treatment modalities (12–16).
Systematic assessment of a core symptom set across all trials 
where patient-reported endpoints are included would 1) encourage 
the inclusion of the patient’s perspective consistently across clinical 
trials and facilitate comparative effectiveness research; 2) enhance our 
understanding of the impact of cancer and its treatment on patients’ 
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lives, which in turn may help identify effective treatment and support-
ive care strategies; and 3) enhance data harmonization across trials, 
permitting integrated data analysis and meta-analysis. Ultimately, this 
would lead to more efficient and robust research approaches.
Several national organizations, including the Center for Medical 
Technology Policy (17), the Food and Drug Administration (18), the 
Patient-Centered Outcomes Research Institute (19), the National 
Quality Forum (20), the American Society of Clinical Oncology 
(21), and the International Society for Quality of Life Research 
(22,23) have issued statements establishing the importance of 
PROs as an essential outcome metric in clinical research and to 
guide decision-making in clinical practice and evaluations of care 
quality. A number of these guidance documents also recommend 
that a consistent core set of PROs be included in electronic health 
records, registries, and national population surveillance initiatives.
We undertook a data-driven, consensus-building process that 
included a systematic review of the published literature, analysis 
across several large datasets, and a multistakeholder meeting to 
identify a recommended core set of symptoms across disease sites 
to be assessed in cancer clinical trials that include a PRO.
Methods
Through a US National Cancer Institute’s (NCI’s) Clinical Trials 
Planning Meeting (CTPM), a panel of stakeholders, including 
researchers, clinicians, and patient representatives, was convened 
to develop recommendations. A  systematic, multistep iterative 
process was used over an 18-month period that included: 1) a sys-
tematic literature review to determine the prevalence and severity 
of symptoms across published studies; 2) an analysis of two NCI 
trial databases that contained clinician reporting of symptomatic 
adverse events, together with four large datasets measuring patient-
reported symptoms in diverse cancer populations across the United 
States and Europe; and 3) a multistakeholder CTPM to review the 
evidence and build consensus.
A subset of the stakeholders (represented by authors of this 
article) served as an expert panel, conducting the literature review 
and data analysis and drafting the initial recommendations to be 
discussed at the multistakeholder CTPM. After the meeting, the 
expert panel synthesized the CTPM’s conclusions and finalized a 
proposed list of core symptoms across disease sites.
Three additional expert panels were constituted for the CTPM 
to address core symptom and HRQOL domains for three specific 
cancer sites (head and neck, prostate, ovarian). Although symptom 
and HRQOL domains to be assessed in clinical trials are proposed 
by the site-specific expert panels, for reasons of feasibility, the 
expert panel that was convened to address the core set across all 
diseases limited their scope of work to symptoms.
Systematic Literature Review
The initial step in this process, a systematic review of the literature, is 
described elsewhere (24). Search terms included “multiple symptoms” 
and “cancer” and was limited to adults (aged 18 years or older) and to 
reports published in English between 2001 and 2011. This strategy 
identified 55 publications, including the Kim et al. systematic review 
of the symptom experience reported in adult cancer studies published 
from 1990 to 2007 (14). A limitation of the work of Kim et al. (14) 
is that their review was restricted o studies that used one of three 
PRO measures: the Symptom Distress Scale (25), the M. D. Anderson 
Symptom Inventory (26), and the Memorial Symptom Assessment 
Scale (27). Eighteen research articles were included in the Kim et al. 
(14) review, representing a total of 3506 patients with a mean age of 
59 years (range = 47–67 years) and 48% of whom were women.
The Reilly et al. review (24) extended the work by Kim et al. (14) 
by synthesizing 21 additional US-based and multinational studies 
and by including studies that used any PRO measure of symptoms. 
The pooled sample characteristics of Kim et al. (14) and Reilly et al. 
(24) were fairly comparable; the Reilly et  al. review (24) reflected 
pooled data of 4067 cancer patients, of whom 62% were women with 
a mean age of 58 years (range = 18–97 years). Reilly et al. identified 
47 symptoms that were ranked by prevalence and severity (24).
Primary Data Sources
Six large research datasets (see Table 1) were obtained, including data 
from two NCI clinician-reported adverse event reporting systems, 
three PRO measure validation studies (28–31), and one symptom 
assessment observational study (32). Within each dataset, the preva-
lence, severity, or importance of symptoms across a variety of cancer 
populations was tabulated. The characteristics, emphasis, and limita-
tions of each of these datasets are described in the Supplementary 
Methods (available online) and summarized in Table 1.
These six datasets offered diversity and representativeness with 
respect to demographics, disease site and stage, participation in 
clinical trials, and receipt of contemporary oncology treatment 
regimens. In addition, these datasets reflected a variety of symptom 
assessment measures, thereby increasing confidence in the gener-
alizability of our conclusions.
Symptom prevalence and severity were then tabulated using 
findings from the systematic literature review and the primary 
datasets. Based on the literature review and analysis of the datasets, 
a panel of experts (represented by the authors of this article) came 
to consensus on a first draft of recommendations for symptoms to 
be measured across disease sites to be presented for stakeholder 
input. Additional criteria considered by the expert panel in propos-
ing a provisional core set of symptoms are provided in Table 2.
Multistakeholder CTPM
To solicit multistakeholder input on the draft recommendations, in 
September 2011, the NCI’s Symptom Management and Health-
Related Quality of Life Steering Committee sponsored a CTPM 
to address two aims: 1) identify a recommended core set of patient-
reported symptoms to be assessed in cancer clinical trials and 2) iden-
tify a core set of site-specific symptoms and/or HRQOL domains 
that should be assessed in clinical trials for head and neck, prostate, 
and ovarian cancers. The meeting included interdisciplinary inves-
tigators in cancer outcomes research and clinical trials, represent-
ing expertise in developmental therapeutics, cancer symptom and 
HRQOL assessment, measurement methodology, and statistics, 
as well as representatives from the patient advocacy community, 
clinical trial cooperative group administration, the pharmaceutical 
industry, the NCI, and the US Food and Drug Administration.
At the CTPM, the four expert panels (one tasked with identifying 
the cross-cutting patient-reported symptoms and three others tasked 
with identifying PRO domains for head and neck, prostate, and 
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ovarian cancers) reported results of the systematic literature reviews 
and presented the rank-ordering of the prevalence or importance of 
the PRO domains based on analysis of the datasets. From the litera-
ture review and the empirically derived rankings, a provisional list of 
symptoms to be measured across all disease sites was proposed for 
discussion. To be included in the provisional list, the symptom must 
have met the criteria listed in Table 2. Feedback from CTPM par-
ticipants was collected for subsequent review by the expert panels.
Expert Panel Deliberations After the Meeting and 
Endorsement by Relevant NCI Committees
After the consensus meeting, the expert panel finalizing the cross-
cutting patient-reported symptoms met monthly by teleconference 
between February 2011 and August 2012. The literature synthesis, 
analysis of data, and stakeholder CTPM feedback were considered 
on a symptom-by-symptom basis to identify a parsimonious final 
core symptom set. To be included in this final core set, the symptom 
Table 1. Characteristics of datasets*
Characteristic CDUS/AdEERS EORTC SOAPP PRO-CTCAE FACT
Data type Clinician-reported 
adverse events in NCI 
clinical trial systems 
database (CDUS and 
AdEERS)
Patient-reported 
symptom data from 
EORTC trials and other 
research studies. These 
data were also used 
to derive QLQ-C30 
reference values
Patient-reported 










Measure CTCAE EORTC-QLQ-C30 MDASI PRO-CTCAE FACT-G and other 
HRQOL questions
Measure type Clinician-reported Patient-reported Patient-reported Patient-reported Patient-reported
Sample size 449 672 AE reports 23 553 patients 3123 patients 595 patients 533 patients
Years of data 2004–2008 1992–2006 2006–2008 January–August 2011 2011
Cancer cite Multiple cancer sites 
(details not available)
14% lung, 14% 
prostate, 12% 
breast, 12% other, 





4% myeloma, 3% 
head & neck, 2% 
leukemia, 2% liver, 
2% lymphoma, 2% 
testicular, 1% brain, 
1% kidney, 1% 
pancreas; <1% each 
of bladder, bone, and 
sarcoma
50% breast, 23% 
colorectal, 17% lung, 
10% prostate
21% breast, 20% lung, 
17% head or neck, 
12% prostate, 7% 
colorectal, and 23% 
other cancer types
10% breast, 10% 
ovarian, 9% brain, 
9% colorectal, 9% 
head and neck, 9% 
hepatobiliary, 9% 
kidney, 9% lung, 
9% lymphoma, 9% 
prostate, 6% bladder
Disease stage Not available 20% stage I–II; 34% 
stage III–IV; 20% 
recurrent/metastatic 
disease
38% advanced disease Not available 100% stage III–IV









Sex Not available 46% female 70% female 53% female 48% female
Age Not available >54% aged 60 years or 
older
Median of 61 years Mean of 59 years Mean of 59 years
* AE = adverse event; CDUS = Clinical Data Update System; AdEERS = Adverse Event Expedited Reporting System; CTCAE = Common Terminology Criteria for 
Adverse Events; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EORTC = European Organization for the Research and Treatment of 
Cancer; FACT = Functional Assessment of Cancer Therapy; FACT-G = Functional Assessment of Cancer Therapy-General; HRQOL = health-related quality of life; 
MDASI = MD Anderson Symptom Inventory; NCI = National Cancer Institute; PRO-CTCAE = Patient-Reported Outcomes version of the Common Terminology 
Criteria for Adverse Events; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer - Quality of Life Questionnaire - Core 30; SOAPP 
= Symptom Outcomes and Practice Patterns study.
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must have met the criteria listed in Table 2 and be endorsed by par-
ticipants at the stakeholder meeting. The expert panel also recom-
mended that the core set be as small as possible to limit respondent 
burden. In their deliberations, the expert panel also established that 
the core symptom set should be assessed alongside other hypoth-
esis-driven disease- and treatment-targeted symptom, functioning, 
and HRQOL domains, when appropriate.
The recommended core symptom set for adult cancer treat-
ment trials was endorsed by NCI’s Symptom Management and 
Health-Related Quality of Life Steering Committee, Clinical and 
Translational Research Operations Committee, and Clinical Trials 
and Translational Research Advisory Committee.
results
Data from the systematic literature review and datasets were 
summarized and presented to the stakeholder CTPM attendees 
charged with synthesis of the information and decision-making to 
prioritize the core symptoms. After the CTPM, the provisional list 
was finalized by the expert panel, who took into account the five 
criteria listed in Table 2.
Prevalence and Severity of Symptoms
Table  3 integrates the results of the synthesis across the litera-
ture reviews and dataset analyses, detailing the top-ranked symp-
toms identified from each source based on prevalence, severity, or 
importance. Terminology mapping from the Medical Dictionary 
for Regulatory Activities was used to determine synonymous symp-
tom terms across studies that used different nomenclature (eg, 
dyspnea = shortness of breath; anorexia = decreased appetite).
Final Core Set of Symptoms
The 12 symptoms included in the final core set are listed above the 
horizontal, bold line in Table 3 and include the following: fatigue, 
insomnia, pain, anorexia, dyspnea, cognitive problems (includes 
memory or concentration impairment), anxiety (includes worry), 
nausea, depression, sensory neuropathy, constipation, and diarrhea. 
Notwithstanding their prevalence, severity, and/or importance, 
symptoms that were prevalent in particular subpopulations but 
not across all diagnostic groups (eg, cough) that might introduce 
fixed effects because of prior treatment (alopecia) or that reflect 
nonspecific effects of a variety of medications or comorbidities (eg, 
dry mouth, drowsiness) were not included in the core list. For par-
simony, and because it was reflected in the top 10 most prevalent, 
severe, or important symptoms in only one dataset, vomiting was 
excluded from the final set.
Discussion
In many clinical trials, the patients’ overall response to therapy 
may entail the reduction of disease-specific symptoms as well as 
the development of symptomatic treatment-related complications. 
Thus, the inclusion of patient reporting provides enhanced under-
standing of the overall treatment effect. Although there is growing 
scientific interest in the inclusion of PRO assessments in cancer 
trials (33–36), to date, no consensus has been reached with regard 
to the optimal core set of symptoms that should be considered for 
measurement across clinical trials. The consensus-building process 
described here included a systematic literature review, analysis and 
synthesis across several large datasets, a multistakeholder meeting 
with academic, community, government, and patient representa-
tion, and an expert panel synthesis and summary of the information.
The result is a recommended core set of 12 symptoms to be 
considered for inclusion in NCI-sponsored treatment trials that 
include PROs. It is hoped that both the methodology we used 
and our study results will help to inform similar strategic planning 
in other organizations internationally (37–39) and complement 
recently proposed guidance for PRO reporting in cancer clinical 
trials (40–42). Cancer clinical trials conducted through the NCI 
Canada Clinical Trials Group and the European Organization for 
the Research and Treatment of Cancer have developed a systematic 
approach to the inclusion of PROs in their trials (43,44).
The principal limitation of this work is the dependence on exist-
ing publications and datasets. For a majority of these sources, the 
number and characteristics of the symptoms being assessed was con-
strained as a function of the questionnaire that was used. However, 
other data sources we examined (30) used qualitative work to iden-
tify important symptoms in an open-ended and patient-centered 
fashion. Our source materials may also have introduced a risk of 
bias because they may not fully reflect the patient experience of less 
common cancers or of treatments developed after 2008. Although 
this work is limited to adult populations, parallel work is identify-
ing important symptoms in pediatric oncology populations (45). 
We also acknowledge that symptoms are not the only important 
HRQOL concern to consider in clinical trials. The group recog-
nizes that physical, mental, and social functioning are other impor-
tant potential outcomes to measure.
A quandary was whether to restrict the core set to those symp-
toms that are direct consequences of a specific cancer-directed 
therapy (eg, nausea, neuropathy). Ultimately, we elected to include 
the direct effects of treatment and aspects of the patient experi-
ence (eg, anxiety, fatigue) that reflect general disease effects but 
that also may vary as a function of treatment-related toxicity or 
the worsening or improvement of tumor-related symptoms (ie, 
symptomatic therapeutic response). In addition to being prevalent 
and important symptoms, anxiety and depression represent aspects 
of the cancer experience that may be worsened or improved by 
cancer-directed therapy, and we argue that capturing such change 
is relevant to trial-level interpretations of treatment benefits and 
burdens (46,47) and can provide valuable information to explain 
trial dropout, nonadherence, toxicity-related treatment delays, and 
missing data (48) or for subgroup analysis (49).
Several important considerations accompany these recom-
mendations. These recommendations are not a directive to meas-
ure symptoms or any PRO in every trial. As with any other trial 
endpoint, PROs should be included when they are expected to 
contribute meaningfully to addressing a trial’s research questions. 
The inclusion of a PRO should be well justified and hypothe-
sis driven and should include an analysis plan that details how 
the results will inform interpretation of therapeutic or toxicity 
endpoints or how the data will develop new knowledge about 
the patient experience with a particular treatment approach. 
These recommendations address the value of a common, con-
sistent, patient-reported symptom documentation across cancer 
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clinical trials. Consistent use will provide a standardized report-
ing approach to evaluate symptoms to promote discovery and test 
hypotheses, facilitate data harmonization, and allow for cross-
trial comparisons and meta-analyses.
Second, specific contexts will warrant evaluation of additional 
symptoms and HRQOL domains beyond this core symptom set. 
These contexts may be shaped by cancer type, disease stage, treat-
ment type, or other characteristics of a study population or a par-
ticular study design. For example, as a component of the current 
initiative, additional HRQOL domains for use alongside the core 
symptoms in three specific disease settings (ovarian, prostate, and 
head and neck cancers) were identified and are reported in this 
issue of the Journal (50–52).
Third, there exists an array of available PRO measures to assess 
symptoms in oncology research (53,54), and these measures have 
been developed through varying approaches (29,30,54,55). This 
initiative does not prescribe which specific measure(s) should be 
used to assess the core symptoms, nor does it recommend the inter-
vals at which symptom data should be collected or advocate for 
particular approaches to parameterizing, analyzing, or interpreting 
symptom outcomes (36,56–58). This initiative also does not specify 
which symptom characteristic(s) (eg, frequency, severity/intensity, 
bother) should be measured and does not specify whether sum-
mative scores, subscale scores, composite endpoints, or symptom 
clusters offer the best approach to representing symptoms (56,59). 
Thus, adoption of these symptom domains for measurement across 
trials will not fully resolve all aspects of measurement heteroge-
neity (36,42). Continued research is needed to refine and validate 
in specific treatment contexts symptom measures that encompass 
these 12 core symptoms and to define which symptom attributes 
most precisely and efficiently capture diverse symptom experi-
ences. Research is also needed to develop novel analytic approaches 
to integrate symptoms into the evaluation of therapeutic response 
and treatment toxicity (36).
Lastly, parsimonious and efficient data collection techniques 
(eg, conditional branching, computerized-adaptive testing) are 
essential to optimize response rates and reduce missing data due 
to participant nonresponse, particularly for follow-up data and in 
populations at the end of life (60,61). With 12 core symptoms, sev-
eral additional context-specific symptoms, and items to represent 
HRQOL and functional status, an item count near 25 items is con-
ceivable. For most patients, completing this number of items by 
paper-, computer-, or phone-based systems takes less than 10 min-
utes and is generally well tolerated, even among those with severe 
symptoms, advanced disease, or impaired performance status (62–
64). Additional feasibility investigations are needed to gauge the 
burden of data collection for clinical trial investigators responsible 
for ensuring that patients complete the scheduled PROs, burden 
to the cooperative groups for monitoring data quality and missing 
data, and burden to statistical centers for additional data manage-
ment and analysis of PROs. It will also be important to assess how 
practical this is across the disease and treatment continuum and 
to identify cost-effective technologies and follow-up strategies to 
minimize missing data.
The overall goal of this initiative is to advance the science of 
PRO measurement and enhance our understanding of the patient 
experience with disease and treatment as reported directly by 
patients. The contemporary emphasis on evidence-driven health-
care delivery and a research context where data sharing, data pool-
ing, and interoperability of datasets are essential make this effort 
particularly timely. Combining studies and datasets based on com-
mon metrics is increasingly important in determining efficacy, 
toxicity, and safety and for making comparisons across treatment 
options. Ultimately, increased consistency of symptom assessment 
across trials will contribute to building a more comprehensive 
evidence base, allow for linkage of PROs to biomarkers and clini-
cal outcomes, and provide an opportunity to improve care quality 
by promoting increased attention to quality-of-life concerns and 
facilitating integration of supportive care (65) for cancer clinical 
trial participants.
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